Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies Prices Public Offering of Stock

NEW YORK – Immune cell sequencing firm Adaptive Biotechnologies said after the close of the market on Thursday that it is selling 8 million shares of common stock at $26.50 per share.

The firm is selling the shares on behalf of certain investors and will not receive any proceeds from the sale.

According to a document filed with the US Securities and Exchange Commission, the selling shareholders include Andris Zoltners, co-chairman of consulting firm ZS Associates and a member of the firm's board of directors, and funds controlled by Viking Global Investors, Matrix Capital Management, and Senator Investment Group. The shareholders have granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares at the offering price, less discounts and commissions.

In morning trading on the Nasdaq, shares of Adaptive were up 10 percent at $29.63.

JP Morgan, Goldman Sachs, and BofA Securities will act as joint lead book-running managers for the offering; Cowen, Guggenheim Securities, and William Blair will act as book-running managers; BTIG will act as comanager.

The offering is expected to close on Jan. 28, subject to customary closing conditions.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more